Clinical Trials

  • A Natural History Study of HNRNP-Related Disorders

    Principal Investigator:

    Jennifer M. Bain, MD, PhD
    A natural history study of hnRNP and other genetic neurodevelopmental disorders.

  • A Study to Identify Genes Underlying Alzheimer's Disease

    Principal Investigator:

    Richard P. Mayeux, MD, MSc
    The goal of this study is to focus on the genetic influences on Alzheimer's disease (AD) risk. We are looking for families and/or individuals (affected or unaffected) of any ethnic background with a family history of Alzheimer's disease and willing to participate.

  • A Study to Test the Effects and Safety of Riliprubart in People with Chronic CIDP for Which the Usual Treatment Does Not Work

    Principal Investigator:

    Thomas H. Brannagan III, MD
    This is a global, multicenter, placebo-controlled, phase 3 study evaluating the efficacy and safety of riliprubart in adult participants with CIDP who are refractory or had an insufficient response to standard of care (SOC) therapies, defined as Ig administered IV (IVIg) or SC (SCIg), or corticosteroids. Treatment duration will be 48 weeks. Participant must be 18 years old at the time of signing the informed consent.

  • ALS Families Project

    Principal Investigator:

    Matthew B. Harms, MD
    This program provides family members of individuals with familial ALS the opportunity to contribute to research focused on learning more about why motor neuron degeneration begins and how or why it progresses. This study provides genetic counseling and testing to help participants understand and manage their risk and determine if they want to learn their genetic status. This study will follow unaffected ALS gene mutation carriers on an annual basis to gather essential information that will ultimately help researchers develop novel therapies for the prevention and treatment of ALS. The ALS...

  • Alzheimer's Disease Research Center (ADRC)

    Principal Investigator:

    Scott A. Small, MD
    For more than 30 years, The Columbia University Alzheimer's Disease Research Center (ADRC) has worked with thousands of participants who have helped provide important insights into how the brain ages and why Alzheimer's disease may develop. We are actively recruiting adults 65 years of age and older who share our commitment to be part of this nationwide study. Younger participants are welcome if there is a personal or family history of memory loss. Participants, both with and without memory problems, will be comprehensively evaluated beginning with a physician taking a history and performing...

  • Alzheimer's Disease Research Center (ADRC) - Healthy Volunteers

    Principal Investigator:

    Scott A. Small, MD
    For more than 30 years, The Columbia University Alzheimer's Disease Research Center (ADRC) has worked with thousands of participants who have helped provide important insights into how the brain ages and why Alzheimer's disease may develop. We are actively recruiting adults 65 years of age and older who share our commitment to be part of this nationwide study. Younger participants are welcome if there is a personal or family history of memory loss. Participants, both with and without memory problems, will be comprehensively evaluated beginning with a physician taking a history and performing...

  • Assess Treatments for Painful Diabetic Peripheral Neuropathy (PDPN)

    Principal Investigator:

    Thomas H. Brannagan III, MD
    The purpose of this study is to Assess Treatments for Painful Diabetic Peripheral Neuropathy (PDPN). To be in this study you must have type II Diabetes Mellitus, PDPN, must be 18 years of age or older, and be able to stop taking some of your current pain medications including pills, creams, patches, marijuana, cannabidiol (CBD) oil, etc. Acetaminophen (commonly known as Tylenol) is the only allowable pain medication other than the study drug.

  • Assess Treatments for Painful Diabetic Peripheral Neuropathy (PDPN)

    Principal Investigator:

    Thomas H. Brannagan III, MD
    The purpose of this study is to Assess Treatments for Painful Diabetic Peripheral Neuropathy (PDPN). To be in this study you must have type II Diabetes Mellitus, PDPN, must be 18 years of age or older, and be able to stop taking some of your current pain medications including pills, creams, patches, marijuana, cannabidiol (CBD) oil, etc. Acetaminophen (commonly known as Tylenol) is the only allowable pain medication other than the study drug.

  • Brain Health and Memory in Diverse Populations

    Principal Investigator:

    Adam M. Brickman, PhD
    The purpose of this study is to better understand how vascular health affects your thinking abilities. We hope that these findings will ultimately lead to treatments aimed to reduce cognitive impairment and dementia. We are actively recruiting adults between the ages of 65 and 90 who note some decline in memory or thinking over the past 3 years and who are of African American, Hispanic/Latino, or European ancestry. You will be asked to return to the Columbia University Medical Center every 12 to 18 months for a total of 3 assessments. At each visit, you will be asked to complete a series of...

  • COVID-19 Vaccine Biomarker Study in Multiple Sclerosis and Other Neuroimmunological Diseases

    Principal Investigator:

    Rebecca Straus Farber, MD
    We need your help today to gather information about the experience of patients with autoimmune diseases of the central nervous system (multiple sclerosis (MS), neuromyelitis optica (NMO), and antiMOG associated disease (MOGAD)) in regards to COVID-19 vaccines. Because individuals with MS, NMO, and MOGAD were not included in the COVID-19 vaccine trials, we want to learn more about the experience of individuals with these autoimmune diseases and the vaccine. Because many patients with central nervous system autoimmune disease also take medications that affect the immune system, we want to find...

Pages